Drug induced phospholipidosis: An acquired lysosomal storage disorder

详细信息    查看全文

• 作者：James A. Shayman ; ^{jshayman@umich.edu} ; Akira Abe
• 关键词：BMP ; bis(monoacylglycero)phosphate ; CAD ; cationic amphiphilic drug ; DIP ; drug induced phospholipidosis ; GXVPLA2 ; group XV phospholipase A2 ; LPLA2 ; lysosomal phospholipase A2 ; MDCK ; Madin Darby canine kidney ; PDMP ; d-threo-1-phenyl-2-decanoylamino-3-morpho
• 刊名：Biochimica et Biophysica Acta (BBA)/Molecular and Cell Biology of Lipids
• 出版年：2013
• 出版时间：March, 2013
• 年：2013
• 卷：1831
• 期：3
• 页码：602-611
• 全文大小：767 K

文摘

There is a strong association between lysosome enzyme deficiencies and monogenic disorders resulting in lysosomal storage disease. Of the more than 75 characterized lysosomal proteins, two thirds are directly linked to inherited diseases of metabolism. Only one lysosomal storage disease, Niemann-Pick disease, is associated with impaired phospholipid metabolism. However, other phospholipases are found in the lysosome but remain poorly characterized. A recent exception is lysosomal phospholipase A2 (group XV phospholipase A2). Although no inherited disorder of lysosomal phospholipid metabolism has yet been associated with a loss of function of this lipase, this enzyme may be a target for an acquired form of lysosomal storage, drug induced phospholipidosis. This article is part of a Special Issue entitled Phospholipids and Phospholipid Metabolism.